Literature DB >> 12594644

Can postexposure vaccination against smallpox succeed?

Philip P Mortimer1.   

Abstract

What can be achieved by the vaccination of individuals exposed to smallpox virus after release of the virus by bioterrorists? There exist several past sources of information on postexposure vaccination failures from which it may be inferred that prompt vaccination of contacts (i.e., individuals exposed to smallpox) often prevented smallpox altogether, that revaccination of previously vaccinated individuals at any time during the first week of the incubation period was largely protective, and that revaccination done even as late as the second week of the incubation period attenuated disease and prevented most deaths. Primary vaccination done within 4 days of exposure was also usually protective at least from serious illness. Modern contingency planning against the release of smallpox virus during a bioterrorist attack should therefore include the capacity for prompt tracing and (re)vaccination of all contacts. Because a growing majority of the population has never before been vaccinated against smallpox and, so, may be unreachable within 4 days, anticipatory vaccination of sections of the populations of potential target countries should be considered if the bioterrorist threat intensifies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594644     DOI: 10.1086/374054

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

Review 1.  The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data.

Authors:  M Shannon Keckler; Mary G Reynolds; Inger K Damon; Kevin L Karem
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

Review 2.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

Review 3.  Postexposure Effects of Vaccines on Infectious Diseases.

Authors:  Tara Gallagher; Marc Lipsitch
Journal:  Epidemiol Rev       Date:  2019-01-31       Impact factor: 6.222

4.  Vaccination by delayed treatment of infection.

Authors:  Sean P Stromberg; Rustom Antia
Journal:  Vaccine       Date:  2011-10-30       Impact factor: 3.641

5.  Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases.

Authors:  Patrick M Reeves; Scott K Smith; Victoria A Olson; Steve H Thorne; William Bornmann; Inger K Damon; Daniel Kalman
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

6.  Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Authors:  Patricia L Earl; Jeffrey L Americo; Linda S Wyatt; Ondraya Espenshade; Jocelyn Bassler; Kathy Gong; Shuling Lin; Elizabeth Peters; Lowrey Rhodes; Yvette Edghill Spano; Peter M Silvera; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-04       Impact factor: 11.205

Review 7.  ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.

Authors:  Aysegul Nalca; Elizabeth E Zumbrun
Journal:  Drug Des Devel Ther       Date:  2010-05-25       Impact factor: 4.162

8.  Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.

Authors:  Scott Parker; Akbar M Siddiqui; Christina Oberle; Ed Hembrador; Randall Lanier; George Painter; Alice Robertson; R Mark Buller
Journal:  Virology       Date:  2008-12-18       Impact factor: 3.616

9.  Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection.

Authors:  Christofer Samuelsson; Jürgen Hausmann; Henning Lauterbach; Michaela Schmidt; Shizuo Akira; Hermann Wagner; Paul Chaplin; Mark Suter; Meredith O'Keeffe; Hubertus Hochrein
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

Review 10.  T-cell epitope vaccine design by immunoinformatics.

Authors:  Atanas Patronov; Irini Doytchinova
Journal:  Open Biol       Date:  2013-01-08       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.